Notes - Consolidated Statement Of Comprehensive Income

TAKARA BIO INC. - Filing #7322771

Concept 2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2022-04-01 to
2023-03-31
Notes - Consolidated statement of comprehensive income
Notes - Consolidated single statement of comprehensive income
Notes regarding amount of revenue from contracts with customers

※1 顧客との契約から生じる収益

売上高については、顧客との契約から生じる収益のみであり、それ以外の収益の計上はありません。顧客との契約から生じる収益の金額は、連結財務諸表「注記事項(収益認識関係)1.顧客との契約から生じる収益を分解した情報」に記載しております。

 

Major components of selling, general and administrative expenses
Research and development expenses included in general and administrative expenses and manufacturing costs for period
Research and development expenses included in general and administrative expenses and manufacturing costs for period
8,324,000,000 JPY
8,575,000,000 JPY
Notes regarding impairment losses

※6 減損損失

当連結会計年度(自 2023年4月1日 至 2024年3月31日)

重要性が乏しいため記載を省略しております。

Notes regarding reclassification adjustments and tax effects relating to other comprehensive income

Talk to a Data Expert

Have a question? We'll get back to you promptly.